Core Laboratories NV (CLB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Core Laboratories NV stock $7.60, price $8.84, that is 14.0% below the price, quality 54 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $8.84 – $34.70 · fair‑value band $5.08 – $11.43 · the $8.84 price screens above the $7.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Core Laboratories in your weekly email
Every Wednesday you see whether Core Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments.
Show moreShow less
The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs.
It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities.
The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment.
It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects.
The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.
Stock analysis
Core Laboratories NV (CLB) currently trades at $8.84, while our model-based Fair Value estimate is $7.60, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $8.49 per share, and 5 of the 24 models we run sit above the $8.84 price.
Bear case: the Asset-Based group reads lowest at $2.24, and 19 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $5.08 (bear) to $11.43 (bull), the price of $8.84 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Energy sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Core Laboratories NV reported revenue of $527M in FY2025 versus $470M in FY2021, a compound +2.9%/yr. Reported net income was $29.7M in FY2025, compounding +10.7%/yr from FY2021.
Key figures
Market cap $396M Small · P/E ratio 17.0 · P/S ratio 0.76 · EPS (TTM) $0.5200 · Dividend yield 0.5% · Net margin 4.7% · Return on equity 9.1% · Return on assets (EBIT) 8.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).
What moves the price
The share trades about 55% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Energy peers we cover trades at −32% fair-value upside, at −14%, CLB screens cheaper than that median.
Fair Value models
Bear$5.08Fair Value $7.60Bull$11.43
Price $8.84 · Downside -14.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.4103 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$3.35$4.75$6.9080
Growth DCF$3.47$4.78$6.6779
Owner Earnings$3.63$5.10$7.3777
All 24 models by family
DCF Models
FCF DCF$3.35$4.75$6.9080
Owner Earnings$3.63$5.10$7.3777
5Y Revenue Exit$5.40$9.09$14.2371
5Y EBITDA Exit$3.50$5.84$8.7874
5Y P/E Exit$3.69$6.17$8.9770
10Y Revenue Exit$4.22$7.05$10.3666
10Y EBITDA Exit$3.39$5.14$7.1168
10Y P/E Exit$3.50$5.33$7.2264
Earnings-Based
Graham-Dodd$4.40$7.97$9.8466
EPV$3.90$4.65$5.2774
Dividend Discount
Gordon GGM$0.3000$0.3800$0.440069
DDM Multi-Stage$0.3000$0.3900$0.470067
Multiples
P/E Multiple$6.79$9.05$11.3263
P/S Multiple$8.24$10.99$13.7458
P/B Multiple$4.50$6.01$7.5155
EV/EBIT$5.17$7.92$10.6765
EV/EBITDA$3.31$5.44$7.5765
EV/Revenue$6.56$10.69$14.8253
Asset-Based
NCAV (Graham)$1.67$2.24$3.3454
Growth DCF
Growth DCF$3.47$4.78$6.6779
Rev-Margin DCF$5.40$9.18$13.6472
Economic Profit
Residual Income$4.92$5.40$6.2376
ROIC Compounder$3.90$4.65$5.2772
Growth Earnings
Growth-Adj P/E$4.90$6.99$9.0967
The fair value above starts from this blend and is adjusted for a cyclical trough year.
In the last 6 months, one officer or director bought shares worth $53,900, on Jul 31, 2026.
BuyLawrence BrunoChairman and CEO, Director5,000 shares at $10.78$53,900Jul 31, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Start year 2020 (pandemic). Over 10 years: −4.1% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−8.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.8%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.0% vs −13.4%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−16% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 7.3%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +20.7% a year for the price and −1.0% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas Equipment & Services · 166 stocks
Beats the industry median on 5/15 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−14.0% · Below median
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets5.1% · Above median
Net margin (12 months)4.7% · Below median
Operating margin (12 months)7.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)−4.3% · Below median
Dividend yield (12 months)0.5% · Bottom 25%
Balance sheet
Debt / equity0.42× · Above median
Valuation Multiplesvs Oil & Gas Equipment & Services median · lower = cheaper
P/E (12 months)17.0× · Cheaper than median
P/B1.49× · Pricier than median
P/S (12 months)0.76× · Cheaper than median
Price / free cash flow (fiscal year)17.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Core Laboratories NV (CLB) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $7.60 versus a price of $8.84, about 14% lower (overvalued).
What is the fair value of CLB?
Our model-based fair value for Core Laboratories NV is $7.60 (as of Nov 4, 2026), built from audited fundamentals. The current price: $8.84.
What is the quality score of CLB?
Core Laboratories NV has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Core Laboratories NV (CLB)?
Our model-based price target is the fair value of $7.60 (as of Nov 4, 2026) from 24 valuation models. Cautious scenario $5.08, optimistic scenario $11.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Core Laboratories NV stock forecast for 2026?
Our models put fair value at $7.60, about 14% lower versus a price of $8.84 (overvalued). Cautious scenario $5.08, optimistic scenario $11.43. The calculation is refreshed regularly with new filings.
What is the revenue of Core Laboratories NV (CLB)?
Core Laboratories NV reported trailing-twelve-month revenue of about $519M (latest available figure, as of Nov 4, 2026).
Does Core Laboratories NV pay a dividend?
Core Laboratories NV currently shows a dividend yield of 0.45% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Core Laboratories NV (CLB) and when is the ex-dividend date?
Core Laboratories NV pays a dividend of $0.04 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Aug 10, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 7.7% of earnings. Free cash flow covers the dividend 12.31 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Core Laboratories NV (CLB)?
For today's price to be fair in a discounted-cash-flow model, Core Laboratories NV would have to grow free cash flow by +23.6 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.6 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of CLB use?
Our models discount Core Laboratories NV at 11.6 %: a base by market capitalisation (small), damped by beta 1.14, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Core Laboratories NV that is +23.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Core Laboratories NV (CLB) delivered so far?
Over the past 5 years revenue at Core Laboratories NV grew +1.6 % a year. The price currently implies free-cash-flow growth of +23.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Core Laboratories NV (CLB) growing?
The median revenue growth in the sector is +14.1 % a year. That is the yardstick for the growth priced into Core Laboratories NV (+23.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Core Laboratories NV (CLB)?
The free-cash-flow yield on the price is 5.45 %: that much free cash flow Core Laboratories NV produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Core Laboratories NV (CLB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Core Laboratories NV it is $7.60 per share (as of Nov 4, 2026), against a price of $8.84. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Core Laboratories NV stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CLB trades above its calculated fair value: price $8.84, fair value $7.60, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLB?
No. The price is what the market pays today ($8.84); the fair value is what the company's own numbers justify ($7.60). For Core Laboratories NV the two are $1.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Core Laboratories NV worth?
The market values Core Laboratories NV at about $396M (market capitalisation, as of Nov 4, 2026). Per share that is $8.84; our models calculate a fair value of $7.60 per share.
What do the bullish and bearish scenarios say about CLB?
Our models span a range for Core Laboratories NV: cautious scenario $5.08, base $7.60, optimistic $11.43 per share (as of Nov 4, 2026, price $8.84). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLB?
Core Laboratories NV trades at a price-to-earnings ratio of 17.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.60 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, 4 of the years ex one-offs: 33.4. Other multiples: PEG 1.7, P/B 1.5, P/S 0.8, EV/EBITDA 8.5.
What is the PEG ratio of CLB?
The PEG ratio of Core Laboratories NV is 1.67 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Core Laboratories NV (CLB)?
Balance-sheet figures for Core Laboratories NV (as of Nov 4, 2026): return on equity 9.1%, debt of 0.42 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is CLB from its 52-week high?
Core Laboratories NV trades at $8.84, about 55% below its 52-week high of $19.64 and at the low of $8.84 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.60 is for.
Which stocks are comparable to Core Laboratories NV?
From the same area (Energy) we also value SLB N.V, Baker Hughes Company, Halliburton Company, Tenaris S.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Core Laboratories NV stock attractive at the current price?
The data as of Nov 4, 2026: price $8.84, calculated fair value $7.60 (−14%), Quality Score 54/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLB calculated?
We run Core Laboratories NV through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.60 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Core Laboratories NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Core Laboratories NV (CLB)?
The closing price on Nov 6, 2026 was $8.84. Our model-based fair value is $7.60, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Core Laboratories NV right now?
Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($5.08 to $11.43) leaves room in how you read the outcome.
Where does the earnings growth of Core Laboratories NV (CLB) come from?
Earnings per share at Core Laboratories NV grew −16.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share −5.8 %, EBIT margin −8.8 %, tax rate −0.6 %, residual (interest, one-offs) −1.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Core Laboratories NV
How large is the market capitalisation of Core Laboratories NV (CLB)?
The market capitalisation of Core Laboratories NV is $396M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Core Laboratories NV (CLB)?
The price-to-sales ratio of Core Laboratories NV is 0.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Core Laboratories NV (CLB)?
Earnings per share at Core Laboratories NV are $0.5200 (price ÷ EPS = P/E 17.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Core Laboratories NV (CLB)?
The dividend yield of Core Laboratories NV is 0.5% (payout 7.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Core Laboratories NV (CLB)?
The net margin of Core Laboratories NV is 4.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Core Laboratories NV (CLB)?
The return on equity (ROE) of Core Laboratories NV is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Core Laboratories NV (CLB)?
On an EBIT basis the return on assets of Core Laboratories NV is 8.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Core Laboratories NV (CLB)?
The operating margin of Core Laboratories NV is 7.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Core Laboratories NV (CLB)?
Revenue at Core Laboratories NV is growing −4.3% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Core Laboratories NV (CLB)?
Earnings per share at Core Laboratories NV are growing −41.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Core Laboratories NV (CLB) carry?
The net debt of Core Laboratories NV is $141M (fiscal year 2025, ≈ 6.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Core Laboratories NV in the live analysis
One click puts Core Laboratories NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026